GRAIL Announces First Health System to Offer Galleri, Novel Multi-Cancer Early Detection Blood Test

Press Release from Grail, a member Bio Nebraska

MENLO PARK, Calif.–GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced a partnership with leading health system Providence to advance the science and delivery of cancer care. Providence, based in Renton, Washington, will be the first health system to offer Galleri, GRAIL’s multi-cancer early detection blood test, as a complement to recommended single cancer screening tests.

The Galleri test initially will be used by Providence at its California, Washington, and Oregon points of care, and could eventually be available across Providence’s entire seven-state footprint that includes more than 50 hospitals and nearly 1,100 health clinics serving 5 million patients. Providence aims to pursue effective ways to identify cancer earlier in patient lives, and will integrate the Galleri test into clinical care to help drive earlier detection of multiple cancers and to try to improve and save lives.

“Today, the majority of cancers are found too late when outcomes are often fatal, and as a result, cancer is projected to become the leading cause of death worldwide,” said Hans Bishop, chief executive officer at GRAIL. “Providence is a leading health system that shares our commitment to improving and saving lives, and our partnership moves us that much closer to making a tremendous and potentially life-altering difference for patients and providers. We are encouraged by interest in Galleri from health systems, medical practices, and self-insured employers, and excited by the progress in our mission to detect cancer early.”